Lindbrook Capital LLC Has $98,000 Holdings in Incyte Co. (NASDAQ:INCY)

Lindbrook Capital LLC increased its holdings in Incyte Co. (NASDAQ:INCY) by 118.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,566 shares of the biopharmaceutical company’s stock after purchasing an additional 848 shares during the period. Lindbrook Capital LLC’s holdings in Incyte were worth $98,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of INCY. Pacer Advisors Inc. boosted its stake in shares of Incyte by 2,858.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,025,784 shares of the biopharmaceutical company’s stock valued at $64,409,000 after purchasing an additional 991,110 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in Incyte by 585.8% during the third quarter. Los Angeles Capital Management LLC now owns 1,145,362 shares of the biopharmaceutical company’s stock valued at $66,168,000 after acquiring an additional 978,342 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Incyte by 56.6% during the 3rd quarter. Acadian Asset Management LLC now owns 2,684,621 shares of the biopharmaceutical company’s stock worth $155,053,000 after acquiring an additional 970,668 shares during the period. Federated Hermes Inc. raised its position in shares of Incyte by 145.2% in the 3rd quarter. Federated Hermes Inc. now owns 864,710 shares of the biopharmaceutical company’s stock worth $49,954,000 after acquiring an additional 512,083 shares in the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of Incyte by 85.3% in the 3rd quarter. Royal Bank of Canada now owns 987,052 shares of the biopharmaceutical company’s stock valued at $57,021,000 after purchasing an additional 454,416 shares during the period. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Incyte Stock Up 0.2 %

Incyte stock opened at $51.74 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.36 and a current ratio of 3.55. The stock has a market cap of $11.62 billion, a PE ratio of 19.52, a price-to-earnings-growth ratio of 1.19 and a beta of 0.65. Incyte Co. has a fifty-two week low of $50.27 and a fifty-two week high of $75.74. The firm’s 50-day simple moving average is $57.06 and its 200 day simple moving average is $57.78.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.09). The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Incyte had a return on equity of 12.56% and a net margin of 16.17%. Incyte’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.44 EPS. Research analysts predict that Incyte Co. will post 3.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on INCY shares. Citigroup lowered their target price on Incyte from $82.00 to $81.00 and set a “buy” rating for the company in a report on Wednesday, February 14th. Stifel Nicolaus lifted their price objective on shares of Incyte from $67.00 to $68.00 and gave the company a “hold” rating in a research note on Wednesday, February 14th. Truist Financial cut their target price on shares of Incyte from $91.00 to $84.00 and set a “buy” rating on the stock in a research note on Wednesday, February 14th. Cantor Fitzgerald assumed coverage on shares of Incyte in a research note on Tuesday. They issued a “neutral” rating for the company. Finally, JMP Securities downgraded Incyte from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. Nine equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $75.50.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.